← Back to Search

Nicotinic Acetylcholine Receptor Agonist

Active Nicotine Group for Memory Disorders

Phase 1
Waitlist Available
Led By Paul Newhouse, MD
Research Sponsored by National Institute on Aging (NIA)
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
All Individual Drugs Already Approved
Approved for 5 Other Conditions

Summary

The purpose of this 12-month study is to determine whether nicotine, administered in the form of nicotine patches, can improve symptoms of memory loss in some people experiencing mild memory problems (referred to in this study as "mild cognitive impairment" or MCI).

Eligible Conditions
  • Memory Disorders

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Side effects data

From 2016 Phase 4 trial • 47 Patients • NCT01362959
100%
Electrolyte disturbance
100%
Gastrointestinal event
100%
Cardiovascular
100%
Other adverse events
31%
Pulmonary
23%
Renal
8%
Death due to respiratory failure
8%
Reintubation
8%
Ischaemic colitis
4%
Stoma necrosis
4%
Duodenal perforation
4%
Asystole
4%
Death due to septic shock
4%
haemorrhagic shock
100%
80%
60%
40%
20%
0%
Study treatment Arm
Control
Nicotine Replacement

Awards & Highlights

All Individual Drugs Already Approved
Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
Approved for 5 Other Conditions
This treatment demonstrated efficacy for 5 other conditions.

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: Active Nicotine GroupExperimental Treatment1 Intervention
Blinded active nicotine for first six months of study; open-label active nicotine for second six months
Group II: Placebo GroupPlacebo Group1 Intervention
Placebo for first six months of study; moved to open-label active nicotine for second six months
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Nicotine
FDA approved

Find a Location

Who is running the clinical trial?

National Institute on Aging (NIA)Lead Sponsor
1,783 Previous Clinical Trials
28,184,148 Total Patients Enrolled
27 Trials studying Memory Disorders
6,011 Patients Enrolled for Memory Disorders
Paul Newhouse, MDPrincipal InvestigatorUniversity of Vermont
4 Previous Clinical Trials
674 Total Patients Enrolled
~3 spots leftby Nov 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top